Hsp90 inhibitors as senolytic drugs to extend healthy aging

Heike Fuhrmann-Stroissnigg, Laura J. Niedernhofer, Paul D. Robbins

Research output: Contribution to journalReview articlepeer-review

52 Scopus citations


Aging is characterized by progressive decay of biological systems and although it is not considered a disease, it is one of the main risk factors for chronic diseases and many types of cancers. The accumulation of senescent cells in various tissues is thought to be a major factor contributing to aging and age-related diseases. Removal of senescent cells during aging by either genetic or therapeutic methods have led to an improvement of several age related disease in mice. In this preview, we highlight the significance of developing senotherapeutic approaches to specifically kill senescent cells (senolytics) or suppress the senescence-associated secretory phenotype (SASP) that drives sterile inflammation (senomorphics) associated with aging to extend healthspan and potentially lifespan. Also, we provide an overview of the senotherapeutic drugs identified to date. In particular, we discuss and expand upon the recent identification of inhibitors of the HSP90 co-chaperone as a new class of senolytics.

Original languageEnglish (US)
Pages (from-to)1048-1055
Number of pages8
JournalCell Cycle
Issue number9
StatePublished - May 3 2018

Bibliographical note

Funding Information:
This work was supported by the National Institute on Aging [AG043376].

Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.


  • Aging
  • DNA damage
  • Mitochondria
  • apoptosis
  • cell senescence


Dive into the research topics of 'Hsp90 inhibitors as senolytic drugs to extend healthy aging'. Together they form a unique fingerprint.

Cite this